|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| General and administrative | |||||
| Legal expense | |||||
| Insurance recovery related to legal settlement | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Grant income | |||||
| Other income, net | |||||
| Sermonix pre-funded warrant change in fair value | |||||
| Net loss | |||||
| Unrealized (loss) gain on available-for-sale securities | |||||
| Comprehensive loss attributable to common stockholders | |||||
| Net loss per share attributable to common stockholders, basic | |||||
| Net loss per share attributable to common stockholders, diluted | |||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | |||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | |||||
Loading...
